Compare IDEXX Laboratories, Inc. (IDXX) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Toro Company (The) Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.4× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Toro Company (The) Common Stock for 0 Days on average.
| IDXX | TTC | |
|---|---|---|
Market Cap | $40.99B | $9.27B |
Volume | 445,410 | 688,325 |
Sector | Health | Industrials |
52-Week High | $766.68 | $101.76 |
52-Week Low | $504.70 | $67.99 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $41.89B | $10.17B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
